Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nautilus Biotechnology filings document SEC reporting for a Nasdaq-listed life sciences tools company developing single-molecule proteome analysis technology. Recent Form 8-K reports furnish quarterly and annual financial results and record material events, including continued-listing compliance with Nasdaq rules.
Proxy materials cover annual meeting procedures, director elections, stockholder voting matters, and board governance. The filings also identify the company's registered common stock under ticker NAUT and provide formal records of its capital structure, governance actions, and public-company reporting obligations.
Nautilus Biotechnology (NAUT) filed its Q3 2025 10‑Q, reporting continued development-stage operations with no product revenue and a narrower quarterly loss. Net loss was $13.6 million for the quarter and $45.2 million for the nine months. Operating expenses decreased to $15.5 million in Q3, driven by lower R&D ($9.6 million) and G&A ($5.9 million), reflecting cost optimizations and prior workforce reductions.
As of September 30, 2025, the company held $131.4 million in cash, cash equivalents, and short‑term investments, and stated these resources are sufficient to fund operations for at least the next twelve months. Total assets were $200.9 million and stockholders’ equity was $169.1 million. Interest income was $1.9 million in Q3, down year over year on lower balances and yields.
Nautilus remains in the collaboration phase for its proteomics platform and expects early access offerings in the first half of 2026 (including Tau assays) with a broader launch targeted for late 2026. Shares outstanding were 126,305,122 as of October 23, 2025.
Nautilus Biotechnology, Inc. filed a current report to share that it has released its financial results for the quarter ended September 30, 2025. The company reported these results through a press release dated October 28, 2025, which is included as Exhibit 99.1.
The report explains that this earnings information is being furnished, not filed, which affects how it is treated under securities laws and future regulatory filings. The filing itself does not detail the financial figures, directing readers instead to the accompanying press release.
Nautilus Biotechnology insider purchases increased Sujal Patel's stake. The filing shows the CEO, President, Secretary and a director acquired 116,500 shares on 09/05/2025 at a weighted average price of $0.6742 and 83,500 shares on 09/08/2025 at a weighted average price of $0.683, bringing his reported direct beneficial ownership to 10,341,721 shares. The filing also discloses indirect holdings of 1,814,035 shares held in the Sujal Patel 2020 Children\'s Trust and 5,280,476 shares held by PFV I, LLC, where he is manager. The form was signed by an attorney-in-fact on 09/09/2025.
Matthew B. Murphy, listed as General Counsel and Trustee of the Murphy Family Trust, reported transactions in Nautilus Biotechnology, Inc. (NAUT) on 09/04/2025.
He purchased 20,000 shares of Nautilus common stock at $0.6429 per share and disposed of 1,250 shares on the same transaction date. After the reported purchase, the filing shows beneficial ownership of 74,140 shares held indirectly through the Murphy Family Trust.
Form 4 overview: On 06/23/2025, Nautilus Biotechnology, Inc. (ticker NAUT) granted Director Melissa B. Epperly a new equity award.
- Security type: Non-qualified stock option (right to buy common stock).
- Shares underlying option: 45,000.
- Exercise price: $0.6951 per share.
- Term: Expires 06/23/2035 (10-year life).
- Vesting schedule: Monthly vesting in 12 equal instalments, subject to Ms. Epperly maintaining “Service Provider” status, as defined in the company’s 2021 Equity Incentive Plan.
- Post-transaction beneficial ownership (derivative form): 45,000 options held directly.
The filing reports no disposals or open-market purchases of common stock; the only activity is the A-coded (grant) issuance of the option. No Rule 10b5-1 trading plan is indicated. The form was signed on 06/24/2025 by attorney-in-fact Mathew B. Murphy.
Investor takeaway: This is a routine director compensation grant that minimally affects share count but incrementally aligns the director’s incentives with shareholder value creation.
The filing is a Form 4 dated 06/24/2025 reporting insider activity at Nautilus Biotechnology, Inc. (ticker NAUT). Director Matthew L. Posard was granted a stock option covering 45,000 common shares at an exercise price of $0.6951 per share. The option was issued on 06/23/2025, vests in twelve equal monthly installments as long as Mr. Posard remains a “Service Provider,” and expires on 06/23/2035. After the transaction, Mr. Posard beneficially owns 45,000 derivative securities, all held directly. No common shares were bought or sold on the open market; the filing reflects an incentive-based equity award only.
Form 4 snapshot: On 06/23/2025, Nautilus Biotechnology, Inc. (ticker NAUT) filed a Form 4 disclosing that director Matthew S. McIlwain received a new equity award.
- Instrument granted: Non-qualified stock option (right to buy common shares).
- Quantity: 45,000 option units.
- Exercise price: $0.6951 per share.
- Expiration: 06/23/2035 (10-year term).
- Vesting schedule: Subject to the director’s continued “Service Provider” status, one-twelfth (1/12) of the option vests monthly after the grant date, fully vesting over one year.
- Post-transaction holdings: McIlwain now beneficially owns 45,000 derivative securities (options) directly; no non-derivative share activity was reported.
- Transaction code: “A” (grant) – no open-market purchase or sale; zero cash proceeds reported.
The filing indicates routine board compensation designed to align the director’s incentives with shareholder returns. No shares were sold or purchased, and there is no indication of additional indirect ownership or Rule 10b5-1 trading plan usage. Overall, the disclosure is limited to a single option grant and does not introduce immediate dilution or cash flow impact for the company.
Form 4 snapshot – Nautilus Biotechnology, Inc. (NAUT)
On 06/23/2025 director Farzad Nazem received a grant of 45,000 non-qualified stock options with an exercise price of $0.6951 per share. The options expire on 06/23/2035 and vest monthly in 12 equal instalments, contingent on Mr. Nazem’s continued service to the company. Following the grant, the director’s beneficial ownership in derivative securities increased by 45,000 options; no open-market purchase or sale of common stock occurred.
- The filing is an initial disclosure of an equity award rather than a transaction involving NAUT shares on the secondary market.
- The awarded option strike price is close to the company’s recent trading range, suggesting alignment of director incentives with future share appreciation.
- The total grant represents an immaterial <0.1% potential dilution based on NAUT’s ~124 million shares outstanding.
No other securities were acquired or disposed of, and no Rule 10b5-1 trading plan was indicated.
Form 4 overview: Nautilus Biotechnology, Inc. (NAUT) reported that director Karen Akinsanya received a new equity award on 06/23/2025.
- Instrument: Stock Option (right to buy common stock)
- Quantity granted: 45,000 options
- Exercise price: $0.6951 per share
- Expiration: 06/23/2035 (10-year term)
- Vesting schedule: 1/12 of the award vests monthly, provided Akinsanya maintains “Service Provider” status under the company’s 2021 Equity Incentive Plan.
- Ownership after grant: 45,000 derivative securities; no direct common-stock position was disclosed in this filing.
- Transaction code: “A” (acquisition), indicating an award rather than an open-market purchase or sale.
- Signatory: Mathew B. Murphy (Attorney-in-Fact) on 06/24/2025.
Investor takeaways: The filing records a routine director compensation grant. It does not involve a cash transaction, does not change outstanding share count immediately, and entails limited short-term financial impact. The options could become dilutive if exercised, but that would occur only once the exercise price is met and the director elects to convert.